Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds

概述：这个快速项目旨在测试自组装肽水凝胶的可行性 治疗伤口。伤口护理目前是一个昂贵的，多步骤的过程中，伤口处理 使用连续产品1）用抗生素去除病原体，2）促进健康的细胞环境 通过水凝胶应用，和3）用皮肤替代物闭合伤口。因此，申报产品 G4 Derm能够同时通过生物物理破坏 细菌膜，同时促进宿主组织再生，而无需添加抗生素或生物制剂。 本产品可用于住院和门诊伤口护理诊所，治愈药物感染的患者 耐药细菌，并减少100，000截肢每年在美国进行，由于慢性 伤口 关键词：组织再生，感染，伤口愈合，生物材料，抗菌 应用领域：组织再生和修复，伤口愈合，感染 子主题名称：生物医学（BM）技术 知识价值：该快速通道提案将生成510（k）支持数据，证明安全性和 G4 Derm作为抗微生物细胞支架基质的功效，其同时对抗生素- 耐药菌株，同时保持有利于组织再生。当前产品使用 基于电荷的机制，在接触时裂解细菌膜，并具有多孔结构， 细胞浸润和细胞附着。 更广泛的影响：这个快速通道提案的更广泛的影响将是一部小说的发展。 这是一种抗菌机制，甚至可以从感染的伤口中消除耐药性细菌菌株。 根据疾病控制和预防中心的报告，耐药细菌会导致 每年有200万美国人受到严重感染，估计每年造成23，000人死亡。我们 对抗抗药性细菌的能力正在下降，新的潜在抗生素药物的管道 越来越少了自1998年以来，只有9种新的抗生素获得了FDA的批准，其中只有2种抗生素获得了FDA的批准。 结合了新的作用机制。因此，拟议的产品提供了前所未有的 在促进组织再生的同时消除细菌的组合。做抗菌 由于其机制是生物物理的，因此细菌不太可能对本品产生耐药性。

Overview: This Fast track project aims to test the feasibility of a self-assembly peptide hydrogel for the treatment of wounds. Wound care is currently an expensive, multistep process in which wounds are treated with sequential products to 1) remove pathogens with antibiotics, 2) promote a healthy cellular environment through hydrogel application, and 3) close the wound with skin substitutes. Thus, the proposed product G4Derm is capable of simultaneously removing drug resistant pathogens through biophysical disruption of bacterial membranes, while promoting host tissue regeneration without added antibiotics or biologics. This product can be used in inpatient and outpatient wound care clinics to heal patients infected with drug resistant bacteria, and to reduce the 100,000 amputations performed each year in the US due to chronic wounds. Key words: tissue regeneration, infections, wound healing, biomaterials, antimicrobial Areas of application: tissue regeneration and repair, wound healing, infections Subtopic name: Biomedical (BM) Technologies Intellectual Merit: This Fast track proposal will generate 510(k) enabling data demonstrating safety and efficacy of G4Derm as an antimicrobial cell-scaffolding matrix that is simultaneously toxic to antibiotic- resistant bacterial strains, while remaining conducive to tissue regeneration. The current product uses a charge-based mechanism to lyse bacterial membranes upon contact and has a porous structure to promote cellular infiltration and cell attachment. Broader Impact: The broader impact of this Fast track proposal would be the development of a novel antimicrobial mechanism that can eliminate even drug-resistant bacterial strains from infected wounds. According to the Centers for Disease Control and Prevention Report, antibiotic-resistant bacteria will cause serious infections in 2 million Americans each year, resulting in an estimated 23,000 deaths annually. Our ability to fight antibiotic-resistant bacteria is diminishing, and the pipeline of new potential antibiotic drugs is growing lean. Only 9 new antibiotics have received FDA approval since 1998, of which only 2 of these incorporated novel mechanisms of action. Hence, the proposed product offers the unprecedented combination of simultaneous bacterial elimination while promoting tisue regeneration. As the antibacterial mechanism is biophysical, bacteria are unlikely to develop resistance to this product.